Atyr Pharma (LIFE) has a profit margin of -32003.68%, below the Healthcare sector average of 14.34%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Atyr Pharma's profit margin stands at -32003.68% as of June 2026. That is below the Healthcare sector average of 14.34%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Atyr Pharma sits lower the Healthcare benchmark (14.34%) with a profit margin of -32003.68%. That is roughly 223203.3% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A profit margin of -32003.68% for Atyr Pharma means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Atyr Pharma's profit margin evolved across reporting periods, while the comparison chart places LIFE next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, profit margin is commonly used to spot outliers. Atyr Pharma's reading of -32003.68% (sector avg 14.34%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.